<DOC>
	<DOCNO>NCT00085553</DOCNO>
	<brief_summary>This phase I trial study side effect best dose tipifarnib erlotinib hydrochloride treat patient solid tumor spread place body . Tipifarnib erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Tipifarnib Erlotinib Hydrochloride Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximal tolerate dose R115777 ( tipifarnib ) combination OSI-774 ( erlotinib hydrochloride ) . II . To describe toxicity profile combination . III . To evaluate effect OSI-774 disposition R115777 . IV . To evaluate vitro marker farnesyl transferase ( FT ) inhibition epidermal growth factor receptor ( EGFR ) inhibition . OUTLINE : This dose-escalation study . Patients receive erlotinib hydrochloride orally ( PO ) daily ( QD ) day 1-28 ( day 8-28 course 1 11/4/2013 ) tipifarnib PO twice daily ( BID ) day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ( Closed accrual 2/2/06 ) After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologic proof cancer unresectable standard lifeprolonging therapy available Absolute neutrophil count ( ANC ) &gt; = 1500/uL Platelet count ( PLT ) &gt; = 100,000/uL Total bilirubin = &lt; 2 mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal ( ULN ) Creatinine = &lt; 1.5 x ULN Hemoglobin ( Hgb ) &gt; = 9.0 g/dL Ability provide inform consent Willingness return Mayo Clinic Rochester follow Life expectancy &gt; = 12 week At maximum tolerate dose ( MTD ) : tumor amenable serial biopsy Medically capable willing provide biologic specimen require protocol Note : The goal study include assessment biologic effect surrogate marker agent ( ) test , therefore , contingent upon availability biologic specimen ; patient preexist clinical contraindication ( e.g . anticoagulant therapy ) biopsy exclude participation study ; however , patient develop major complication associate first biopsy ( e.g . bleed ) develop clinical contraindication ( e.g. , anticoagulant therapy ) entry study may remain study without requirement tissue biopsy ; stipulation apply 12 patient enrol Cohort II MTD ; stipulation provision biologic specimen , note , exclude optional pharmacogenomic specimen Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 2 , 3 , 4 Uncontrolled infection Any follow prior therapy : Chemotherapy = &lt; 4 week prior study entry Mitomycin C/nitrosoureas = &lt; 6 week prior study entry Immunotherapy = &lt; 4 week prior study entry Biologic therapy = &lt; 4 week prior study entry Hormonal cancer therapy = &lt; 4 week prior study entry Radiation therapy = &lt; 4 week prior study entry Radiation &gt; 25 % bone marrow Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment New York Heart Association classification III IV Patients enzymeinducing anticonvulsant ( Phenobarbital , Dilantin , Tegretol ) Any follow : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception ( condoms plus spermicidal agent , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , abstinence , etc . ) Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Uncontrolled intercurrent illness include , limited : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement Prior treatment EGFR target therapy ( e.g. , ZD1869 , EKB569 , OSI774 , CI1033 , GW572016 , C225 , EMD72000 ) Farnesyl transferase inhibitor ( R115777 , SCH66336 , BMS2146632 ) Major surgery , significant traumatic injury occur = &lt; 21 day prior study entry Abnormalities cornea base history ( e.g. , dry eye syndrome , Sj√∂gren 's syndrome ) , congenital abnormality ( e.g. , Fuch 's dystrophy ) , abnormal slitlamp examination use vital dye ( e.g. , fluorescein , BengalRose ) , and/or abnormal corneal sensitivity test ( Schirmer test similar tear production test ) Gastrointestinal tract disease result inability take oral nasogastric medication requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption , active peptic ulcer disease Human immunodeficiency virus ( HIV ) positive patient receive combination antiretroviral therapy Known brain metastasis unless treat surgery and/or radiation stable &gt; = 8 week ; patient enzymeinducing anticonvulsant ( Phenobarbital , Phenytoin ( Dilantin ) Carbamazepine ( Tegretol ) )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>